ANAB
AnaptysBio, Inc. NASDAQ Listed Jan 26, 2017$66.92
After hrs
$69.33
+0.00%
Mkt Cap $2.9B
52w Low $11.40
91.1% of range
52w High $72.36
50d MA $46.61
200d MA $29.58
P/E (TTM)
-145.1x
EV/EBITDA
13.4x
P/B
49.9x
Debt/Equity
0.4x
ROE
-35.6%
P/FCF
45.8x
RSI (14)
—
ATR (14)
—
Beta
0.41
50d MA
$46.61
200d MA
$29.58
Avg Volume
863.4K
AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications. Its products include Imsidolimab, an antibody that inhibits the interleukin-36 receptor (IL-36R) for the treatment of various dermatological inflammatory diseases; Rosnilimab, an anti-PD-1 agonist antibody program designed to augment PD-1 signaling through rosnilimab treatment to suppress T-cell driven human inflammatory diseases; and ANB032, an anti-BTLA modulator antibody applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. and Bristol-Myers Squibb; and license agreements with United Kingdom Research and Innovation, as well as Millipore Corporation. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.
10770 Wateridge Circle · San Diego, CA 92121-5801 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 3, 2026 | AMC | 0.89 | 1.58 | +77.5% | 35.22 | +6.2% | +14.6% | +8.4% | +4.9% | +13.0% | +17.4% | — |
| Nov 4, 2025 | AMC | -1.06 | 0.52 | +149.1% | 23.16 | +12.9% | +3.6% | +10.0% | +14.1% | -2.2% | -3.4% | — |
| Aug 7, 2025 | AMC | -1.50 | -1.34 | +10.7% | 13.58 | +1.8% | +3.2% | -1.8% | -1.3% | +1.7% | -2.0% | — |
| May 5, 2025 | AMC | -1.30 | -1.28 | +1.5% | 13.82 | +2.2% | -3.0% | -5.1% | -5.6% | -5.5% | -3.4% | — |
| Feb 27, 2025 | AMC | -1.55 | -0.72 | +53.5% | 10.93 | +18.7% | +2.6% | -10.7% | -7.0% | +2.2% | +0.0% | — |
| Nov 5, 2024 | AMC | -1.72 | -1.14 | +33.7% | 13.25 | +11.8% | +11.8% | +8.2% | +7.2% | +12.7% | +8.2% | — |
| Aug 5, 2024 | AMC | -1.20 | -1.71 | -42.5% | 21.58 | +4.0% | -0.9% | -2.5% | +3.8% | +2.1% | +4.3% | — |
| May 9, 2024 | AMC | -1.54 | -1.64 | -6.5% | 17.49 | -0.3% | -10.7% | -8.6% | -3.7% | -2.4% | -2.9% | — |
| Mar 12, 2024 | AMC | -1.60 | -1.59 | +0.7% | 17.37 | -0.3% | -5.2% | -9.4% | -10.0% | -11.1% | -10.7% | — |
| Nov 2, 2023 | AMC | -1.72 | -1.41 | +18.0% | 10.80 | +8.9% | +8.2% | +2.9% | +1.9% | -4.4% | -8.0% | — |
| Aug 7, 2023 | AMC | -1.70 | -1.50 | +11.5% | 12.31 | +3.2% | +2.6% | -4.2% | -2.1% | +2.9% | +4.4% | — |
| May 11, 2023 | AMC | -1.04 | -1.58 | -51.9% | 13.84 | -0.1% | -6.3% | -6.7% | -10.3% | -8.2% | -8.8% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 28 | Leerink Partners | Maintains | Outperform → Outperform | — | $66.59 | $67.16 | +0.9% | -0.7% | -6.4% | -1.3% | +0.3% | +4.8% |
| Apr 22 | Barclays | Maintains | Overweight → Overweight | — | $51.82 | $51.56 | -0.5% | +3.3% | -1.1% | +13.6% | +28.5% | +27.6% |
| Apr 21 | UBS | Maintains | Buy → Buy | — | $50.95 | $51.08 | +0.3% | +1.7% | +5.1% | +0.6% | +15.6% | +30.7% |
| Mar 31 | Piper Sandler | Maintains | Overweight → Overweight | — | $36.92 | $38.33 | +3.8% | +0.1% | +2.4% | +4.1% | +12.7% | +12.2% |
| Mar 30 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $38.26 | $38.03 | -0.6% | -3.5% | -3.4% | -1.2% | +0.5% | +8.8% |
| Mar 17 | UBS | Maintains | Buy → Buy | — | $43.19 | $43.37 | +0.4% | +3.9% | -0.1% | -0.1% | -3.7% | -3.2% |
| Mar 12 | Wedbush | Maintains | Outperform → Outperform | — | $43.11 | $43.12 | +0.0% | -1.3% | +0.2% | +0.2% | +4.1% | +0.1% |
| Mar 9 | Truist | Maintains | Hold → Hold | — | $36.94 | $36.88 | -0.2% | +7.7% | +11.9% | +16.7% | +15.1% | +17.0% |
| Mar 5 | Stifel | Maintains | Buy → Buy | — | $40.37 | $39.67 | -1.7% | -5.4% | -8.5% | -1.4% | +2.4% | +6.8% |
| Mar 4 | Barclays | Maintains | Overweight → Overweight | — | $35.22 | $37.39 | +6.2% | +14.6% | +8.4% | +4.9% | +13.0% | +17.4% |
| Mar 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $35.22 | $37.39 | +6.2% | +14.6% | +8.4% | +4.9% | +13.0% | +17.4% |
| Jan 20 | Barclays | Maintains | Overweight → Overweight | — | $30.45 | $30.00 | -1.5% | +1.2% | +2.2% | +3.6% | +4.1% | +3.2% |
| Dec 17 | Barclays | Maintains | Overweight → Overweight | — | $30.02 | $29.65 | -1.2% | +1.5% | +5.6% | +9.0% | +11.8% | +11.1% |
| Dec 11 | Stifel | Maintains | Buy → Buy | — | $29.97 | $29.71 | -0.9% | +1.8% | -0.0% | +1.3% | +0.2% | +1.6% |
| Nov 24 | Wedbush | Maintains | Outperform → Outperform | — | $26.41 | $26.49 | +0.3% | +5.9% | +4.8% | +6.4% | +5.1% | +4.3% |
| Nov 24 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $26.41 | $26.49 | +0.3% | +5.9% | +4.8% | +6.4% | +5.1% | +4.3% |
| Nov 11 | Barclays | Maintains | Overweight → Overweight | — | $22.65 | $22.02 | -2.8% | -1.2% | -2.6% | -2.1% | -0.4% | +2.3% |
| Nov 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $22.65 | $22.02 | -2.8% | -1.2% | -2.6% | -2.1% | -0.4% | +2.3% |
| Nov 10 | Truist | Maintains | Hold → Hold | — | $26.43 | $21.33 | -19.3% | -14.3% | -15.4% | -16.5% | -16.1% | -14.7% |
| Nov 5 | Wells Fargo | Maintains | Overweight → Overweight | — | $23.16 | $26.15 | +12.9% | +3.6% | +10.0% | +14.1% | -2.2% | -3.4% |
| Nov 5 | Guggenheim | Maintains | Buy → Buy | — | $23.16 | $26.15 | +12.9% | +3.6% | +10.0% | +14.1% | -2.2% | -3.4% |
| Oct 29 | Stifel | Maintains | Buy → Buy | — | $24.11 | $25.27 | +4.8% | -0.1% | +0.8% | +1.2% | -0.3% | -3.9% |
| Oct 15 | Wedbush | Maintains | Outperform → Outperform | — | $21.23 | $21.03 | -0.9% | +7.7% | +8.0% | +8.8% | +10.8% | +7.1% |
| Sep 30 | Wedbush | Maintains | Outperform → Outperform | — | $15.51 | $17.11 | +10.3% | +31.6% | +37.4% | +34.7% | +33.0% | +30.0% |
| Sep 30 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $15.51 | $17.11 | +10.3% | +31.6% | +37.4% | +34.7% | +33.0% | +30.0% |
| Aug 12 | UBS | Maintains | Neutral → Neutral | — | $13.33 | $13.31 | -0.1% | +0.6% | +3.6% | -0.1% | +0.8% | +0.1% |
| Aug 7 | Wedbush | Maintains | Outperform → Outperform | — | $15.03 | $15.71 | +4.5% | -9.6% | -6.7% | -11.3% | -10.8% | -8.1% |
| Jul 24 | JP Morgan | Maintains | Overweight → Overweight | — | $18.00 | $18.77 | +4.3% | -0.1% | -0.2% | -1.5% | -2.9% | -7.5% |
| Jun 4 | HC Wainwright & Co. | Upgrade | Neutral → Buy | — | $15.68 | $16.43 | +4.8% | -9.6% | -10.1% | +0.8% | -1.4% | +1.9% |
| May 28 | Guggenheim | Maintains | Buy → Buy | — | $13.42 | $14.09 | +5.0% | +3.8% | +12.1% | +10.4% | +8.6% | +16.8% |
| May 6 | Guggenheim | Maintains | Buy → Buy | — | $13.82 | $14.13 | +2.2% | -3.0% | -5.1% | -5.6% | -5.5% | -3.4% |
| May 1 | Wedbush | Maintains | Outperform → Outperform | — | $14.81 | $14.76 | -0.3% | -2.3% | -4.6% | -6.7% | -9.5% | -11.4% |
| Mar 5 | JP Morgan | Maintains | Overweight → Overweight | — | $10.17 | $10.23 | +0.6% | +9.8% | +7.5% | +7.1% | +9.6% | +14.9% |
| Mar 4 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $9.76 | $9.63 | -1.3% | +4.2% | +14.4% | +12.0% | +11.6% | +14.2% |
| Feb 13 | Wells Fargo | Maintains | Overweight → Overweight | — | $10.77 | $11.08 | +2.9% | +19.4% | +31.4% | +22.5% | +21.4% | +16.8% |
| Feb 12 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $8.25 | $8.37 | +1.5% | +30.5% | +55.9% | +71.5% | +59.9% | +58.4% |
| Feb 7 | Wedbush | Maintains | Outperform → Outperform | — | $10.72 | $10.73 | +0.1% | -9.3% | -19.1% | -23.0% | +0.5% | +20.0% |
| Feb 4 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $11.11 | $11.63 | +4.7% | -0.9% | -3.6% | -3.5% | -12.5% | -22.0% |
| Dec 19 | JP Morgan | Maintains | Overweight → Overweight | — | $10.23 | $10.10 | -1.3% | -2.2% | -5.2% | -9.0% | -9.5% | -10.5% |
| Dec 18 | Truist | Maintains | Hold → Hold | — | $10.66 | $10.97 | +2.9% | -4.0% | -6.2% | -9.0% | -12.7% | -13.1% |
| Dec 12 | Guggenheim | Maintains | Buy → Buy | — | $10.34 | $10.39 | +0.5% | -3.2% | +0.5% | +7.4% | +3.1% | -1.1% |
| Dec 12 | Wells Fargo | Maintains | Overweight → Overweight | — | $10.34 | $10.39 | +0.5% | -3.2% | +0.5% | +7.4% | +3.1% | -1.1% |
| Dec 11 | HC Wainwright & Co. | Downgrade | Buy → Neutral | — | $15.39 | $9.55 | -37.9% | -32.8% | -35.0% | -32.5% | -27.9% | -30.7% |
| Dec 2 | BTIG | Downgrade | Buy → Neutral | — | $16.64 | $15.68 | -5.8% | -2.3% | -11.8% | -3.5% | -5.2% | -0.6% |
| Nov 12 | JP Morgan | Maintains | Overweight → Overweight | — | $14.93 | $14.57 | -2.4% | -4.0% | -7.4% | -9.9% | -15.1% | -15.7% |
| Nov 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $13.25 | $14.81 | +11.8% | +11.8% | +8.2% | +7.2% | +12.7% | +8.2% |
| Oct 31 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $14.79 | $14.71 | -0.5% | -2.5% | -2.3% | -10.1% | -10.4% | +0.1% |
| Oct 30 | UBS | Maintains | Neutral → Neutral | — | $20.53 | $15.33 | -25.3% | -28.0% | -29.8% | -29.6% | -35.3% | -35.5% |
| Oct 21 | Guggenheim | Maintains | Buy → Buy | — | $23.32 | $23.80 | +2.1% | +1.1% | +0.5% | -0.6% | -7.9% | -8.4% |
| Sep 26 | Wedbush | Maintains | Outperform → Outperform | — | $21.56 | $21.43 | -0.6% | +0.5% | -1.4% | +3.6% | +7.7% | +8.2% |
No insider trades available.
8-K
AnaptysBio, Inc. -- 8-K Filing
AnaptysBio's pro forma financials indicate a significant corporate transaction occurred, likely an acquisition or merger, requiring investors to review the combined entity's projected balance sheet and operations through December 31, 2025.
Apr 24
8-K
AnaptysBio, Inc. -- 8-K Filing
AnaptysBio completed a spin-off creating First Tracks Biotherapeutics, with detailed agreements governing asset transfers, liability assumptions, and ongoing relationships between the two independent entities.
Apr 20
8-K · 7.01
! Medium
AnaptysBio, Inc. -- 8-K 7.01: Regulation FD Disclosure
AnaptysBio disclosed an investor presentation without material updates, suggesting the company is maintaining consistent messaging with stakeholders on its pipeline and strategic direction.
Mar 3
Data updated apr 24, 2026 6:05pm
· Source: massive.com